Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
Public ClinicalTrials.gov record NCT04598269. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a, Multicenter, Randomized, Double-blind, Vehicle-controlled, Parallel-group Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a first-in-human, randomized, double-blind, parallel-group, vehicle-controlled study to evaluate the efficacy, safety, tolerability, and PK of ATI-1777 solution following twice-daily applications to target areas of participants with moderate or severe atopic dermatitis (AD).
Study identification
- NCT ID
- NCT04598269
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 50 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2020 (Actual)
- Primary completion
- Apr 8, 2021 (Actual)
- Completion
- Apr 22, 2021 (Actual)
- Last update posted
- Sep 28, 2023
2020 – 2021
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Aclaris Investigational Site | Scottsdale | Arizona | 85260 | — |
| Aclaris Investigational Site | Encino | California | 91436 | — |
| Aclaris Investigational Site | Los Angeles | California | 90045 | — |
| Aclaris Investigational Site | Tampa | Florida | 33613 | — |
| Aclaris Investigational Site | Indianapolis | Indiana | 46250 | — |
| Aclaris Investigational Site | Overland Park | Kansas | 66215 | — |
| Aclaris Investigational Site | Omaha | Nebraska | 68144 | — |
| Aclaris Investigational Site | Kew Gardens | New York | 11415 | — |
| Aclaris Investigational Site | Newtown Square | Pennsylvania | 19073 | — |
| Aclaris Investigational Site | Fountain Inn | South Carolina | 29644 | — |
| Aclaris Investigational Site | Austin | Texas | 78759 | — |
| Aclaris Investigational Site | San Antonio | Texas | 78213 | — |
| Aclaris Investigational Site | Lynchburg | Virginia | 24501 | — |
| Aclaris Investigational Site | Newport News | Virginia | 23606 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04598269, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 28, 2023 · Synced Nov 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04598269 live on ClinicalTrials.gov.